Novo Nordisk comes out clean in $1.8B investor lawsuit alleging insulin misdirection

The details are slim, but Novo Nordisk seems to be in the clear after shareholders took the diabetes juggernaut to court nearly three years ago over the company's public communications about its struggling insulin business.

Novo Nordisk said Friday that it’s settled a Danish securities lawsuit from the summer of 2019. The agreement “contains no admission of liability, wrongdoing or responsibility by Novo Nordisk,” and the company won’t make any payments to plaintiffs, the company said in a release.